Lipoprotein lipase-derived fatty acids: Physiology and dysfunction

Current Hypertension Reports

Volumn 9, Issue 6, 2007, Pages 462-466

  Lee, Jee ^b   Goldberg, Ira J ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FATTY ACID; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; LIPOPROTEIN;

ABDOMINAL AORTA; AORTA CONSTRICTION; CARDIOTOXICITY; CELL ENERGY; CONGESTIVE CARDIOMYOPATHY; GLUCOSE METABOLISM; HEART CONTRACTION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HYPERTENSION; KNOCKOUT MOUSE; LIPID METABOLISM; LIPOLYSIS; NONHUMAN; PHENOTYPE; REVIEW; TRANSGENE; ANIMAL; ANIMAL MODEL; GENETICS; HEART; METABOLISM; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; FATTY ACIDS; HEART; LIPOPROTEINS; MICE; MODELS, ANIMAL;

EID: 38049125622     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0085-4     Document Type: Review

References (36)

1. van der Vusse GJ, Glatz JF, Stam HC, Reneman RS: Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 1992, 72:881-940.
2. Lopaschuk GD, Belke DD, Gamble J, et al.: Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994, 1213:263-276.
3. Blanchette-Mackie EJ, Masuno H, Dwyer NK, et al.: Lipoprotein lipase in myocytes and capillary endothelium of heart: immunocytochemical study. Am J Physiol 1989, 256:E818-828.
4. Augustus AS, Kako Y, Yagyu H, Goldberg IJ: Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 2003, 284:E331-339.
5. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996, 37:693-707.
6. Augustus AS, Buchanan J, Park TS, et al.: Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006, 281:8716-8723.
7. Iemitsu M, Miyauchi T, Maeda S, et al.: Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 2002, 283:H1750-1760.
8. Moncrieff J, Lindsay MM, Dunn FG: Hypertensive heart disease and fibrosis. Curr Opin Cardiol 2004, 19:326-331.
9. Noh HL, Okajima K, Molkentin JD, et al.: Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction. Am J Physiol Endocrinol Metab 2006, 291:E755-760.
10. Sukonina V, Lookene A, Olivecrona T, Olivecrona G: Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci U S A 2006, 103:17450-17455.
11. Yu X, Burgess SC, Ge H, et al.: Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc Natl Acad Sci U S A 2005, 102:1767-1772.
12. Ricart-Jane D, Cejudo-Martin P, Peinado-Onsurbe J, et al.: Changes in lipoprotein lipase modulate tissue energy supply during stress. J Appl Physiol 2005, 99:1343-51.
13. Seip RL, Angelopoulos TJ, Semenkovich CF: Exercise induces human lipoprotein lipase gene expression in skeletal muscle but not adipose tissue. Am J Physiol 1995, 268:E229-236.
14. Ruge T, Svensson M, Eriksson JW, Olivecrona G: Tissue-specific regulation of lipoprotein lipase in humans: effects of fasting. Eur J Clin Invest 2005, 35:194-200.
15. Deshaies Y, Geloen A, Paulin A, et al.: Tissue-specific alterations in lipoprotein lipase activity in the rat after chronic infusion of isoproterenol. Horm Metab Res 1993, 25:13-16.
16. Stam H, Hulsmann WC: Effects of hormones, amino acids and specific inhibitors on rat heart heparin-releasable lipoprotein lipase and tissue neutral lipase activities during long-term perfusion. Biochim Biopbys Acta 1984, 794:72-82.
17. Gouni-Berthold I, Oka K, Berthold HK, Chan L: Failure of the nonselective beta-blocker propranolol to affect lipoprotein lipase gene expression in the rat. Lipids 1997, 32:943-947.
18. Cryer A, Jones HM: The distribution of lipoprotein lipase (clearing factor lipase) activity in the adiposal, muscular and lung tissues of ten animal species. Comp Biochem Physiol B 1979, 63:501-505.
19. Husbands DR: The distribution of lipoprotein lipase in tissues of the domestic fowl and the effects of feeding and starving. Br Poult Sci 1972, 13:85-90.
20. Bonnet M, Leroux C, Faulconnier Y, et al.: Lipoprotein lipase activity and mRNA are up-regulated by refeeding in adipose tissue and cardiac muscle of sheep. J Nutr 2000, 130:749-756.
21. Luiken JJ, Coort SL, Willems J, et al.: Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 2003, 52:1627-1634.
22. An D, Pulinilkunnil T, Qi D, et al.: The metabolic "switch" AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am J Physiol Endocrinol Metab 2005, 288: E246-253.
23. Levak-Frank S, Hofmann W, Weinstock PH, et al.: Induced mutant mouse lines that express lipoprotein lipase in cardiac muscle, but not in skeletal muscle and adipose tissue, have normal plasma triglyceride and high-density iipoprotein-cholesterol levels. Proc Natl Acad Sci U S A 1999, 96:3165-3170.
24. Zhou YT, Grayburn P, Karim A, et al.: Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000, 97:1784-1789.
25. Finck BN, Lehman JJ, Leone TC, et al.: The cardiac phenotype induced by PPAR-alpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109:121-130.
26. Finck BN, Han X, Courtois M, et al.: A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003, 100:1226-1231.
27. Nohammer C, Brunner F, Wolkart G, et al.: Myocardial dysfunction and male mortality in peroxisome proliferator-activated receptor alpha knockout mice overexpressing lipoprotein lipase in muscle. Lab Invest 2003, 83:259-269.
28. Yagyu H, Chen G, Yokoyama M, et al.: Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003, 111:419-426.
29. Listenberger LL, Pry DS, Schaffer JE: Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem 2001, 276:14890-14895.
30. Yang J, Sambandam N, Han X, et al.: CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 2007, 100:1208-1217.
31. Lee Y, Naseem RH, Duplomb L, et al.: Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc Natl Acad Sci U S A 2004, 101:13624-13629.
32. Yokoyama M, Yagyu H, Hu Y, et al.: Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem 2004, 279:4204-4211.
33. Rangwala SM, Lazar MA: Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004, 25:331-336.
34. Vikramadithyan RK, Hirata K, Yagyu H, et al.: Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther 2005, 313:586-593.
35. Golfman LS, Wilson CR, Sharma S, et al.: Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 2005, 289:E328-336.
36. Son N, Park T, Yamashita H, et al.: Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction. J Clin Invest 2007, Epub ahead of print.